Journal of Diabetes Investigation: Volume 8, Issue 3 Review
This issue highlights two critical themes in modern type 2 diabetes management: protecting cardiovascular health through blood vessel preservation and understanding the real-world barriers that prevent timely transitions to insulin therapy.
The featured research provides valuable insights on how linagliptin (a DPP-4 inhibitor) can improve the function of the inner lining of blood vessels, helping to guard against vascular complications. Concurrently, a large-scale observational study in Korea uncovers the common clinical and psychological reasons why both patients and physicians delay starting insulin—even when oral drugs are no longer sufficient to control blood glucose.
For patients, families, and healthcare providers, these findings emphasize that diabetes management extends far beyond daily blood glucose numbers. It involves active communication to overcome treatment hurdles and prioritizing therapies that support long-term heart and blood vessel health.
This article was created with the assistance of AI. Although the content is based on original research articles and other academic sources, errors may be present. Please verify the information using the original articles and consult qualified healthcare professionals for medical advice.
Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function
Authors: Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, Ryo Iga, Yuka Kobayashi, Eiichiro Kanda, Hiroshi Uchino, Takahisa Hirose
Research Objective
To evaluate and compare the impact of adding the DPP-4 inhibitor linagliptin to standard therapy versus increasing the dose of metformin on blood vessel function in adults with type 2 diabetes.
Methods
In this 16-week randomized, open-label trial, 96 patients with type 2 diabetes who were already taking 750 mg/day of metformin (and had HbA1c levels between 6.0% and 8.0%) were divided into three groups:
- Control Group (29 patients): Continued taking 750 mg/day of metformin.
- Metformin Group (26 patients): Increased metformin to 1,500 mg/day.
- Linagliptin Add-on Group (29 patients): Continued 750 mg/day of metformin and added 5 mg/day of linagliptin.
Main Findings
Only the group taking the linagliptin add-on showed significant improvement in blood vessel dilation, with average FMD measurements increasing from 4.9% at baseline to 6.3% after 16 weeks. The other groups did not experience significant changes. Additionally, both the metformin-only and linagliptin add-on groups saw safe decreases in HbA1c levels. The positive change in blood vessel function was associated with a reduction in apolipoprotein B (a marker for cholesterol particles that can clog arteries), which decreased uniquely in the linagliptin group.
Clinical Significance
Linagliptin therapy not only helps manage blood sugar levels but also directly supports vascular health by improving the function of the inner blood vessel lining (the endothelium). This effect is likely linked to the reduction of atherogenic cholesterol carriers (apolipoprotein B).
Key Points for Patients
The "endothelium" is the delicate inner lining of your blood vessels. When it functions poorly, the risk of cardiovascular complications increases. If you have type 2 diabetes with mild-to-moderate high blood sugar, adding a medication like linagliptin to your current metformin therapy might provide an extra layer of protection for your cardiovascular system, beyond simply lowering your daily blood sugar readings.
Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents: A prospective observational DIPP-FACTOR study in Korea
Authors: Sin Gon Kim, Nam Hoon Kim, Bon Jeong Ku, Ho Sang Shon, Doo Man Kim, Tae Sun Park, Yong‐Seong Kim, In Joo Kim, Dong Seop Choi
Research Objective
To determine how long it takes to initiate insulin therapy in patients with uncontrolled type 2 diabetes and to pinpoint both patient- and physician-related factors that contribute to delays in starting insulin.
Methods
This large prospective disease registry study monitored 1,959 evaluable type 2 diabetes patients across 69 centers in Korea. All patients had used two or more oral diabetes medications over the past five years, had poorly controlled blood sugar (HbA1c ≥ 8% within the past six months), and had not yet started insulin. Researchers tracked insulin initiation over 12 months.
Main Findings
Only 20% of these patients started insulin during the 1-year study. Among those taking two oral medications, less than half (44.5%) had initiated insulin even after 6 years of eligibility. Key obstacles included:
- Patient-related barriers: Patients who delayed insulin were often older, had a shorter overall duration of diabetes, or had comparatively lower HbA1c levels. The main reasons patients refused insulin were the perceived inconvenience of therapy (51.6%) and fear of injections (48.2%).
- Physician-related barriers: Delayed initiation was linked to physicians aged 50–59, female physicians, and doctors seeing fewer than 1,000 patients per month. The primary physician-reported reasons for delaying therapy were patient refusal (33.6%) and worries about whether the patient would comply with the insulin regimen (26.5%).
Clinical Significance
A substantial delay in starting insulin exists for patients whose diabetes is poorly managed on multiple oral drugs. Addressing psychological barriers (such as needle phobias and lifestyle disruption concerns) and boosting physician-patient communication are critical steps toward improving outcomes.
Key Points for Patients
Starting insulin can be intimidating, but when oral medications are no longer working, delaying insulin can increase your risk of long-term diabetes complications. Concerns about pain, needles, or daily routine disruption are highly common and completely natural. Discussing these specific worries openly with your medical team can help you find modern, easy-to-use insulin options that fit your lifestyle.
